No­var­tis share­hold­ers vote in fa­vor of San­doz spin­off, sep­a­ra­tion set for ear­ly Oc­to­ber

No­var­tis’ San­doz spin­off is right on track fol­low­ing a share­hold­er vote in fa­vor of a full sep­a­ra­tion on Fri­day.

The gener­ics and biosim­i­lars unit is ex­pect­ed to be­come in­de­pen­dent on or around Oct. 4. That’s in line with what CEO Vas Narasimhan tar­get­ed when he first an­nounced plans to spin out San­doz last Au­gust, though talks of a po­ten­tial spin­out had been cir­cu­lat­ing for years be­fore that. The com­pa­ny’s board of di­rec­tors had al­ready unan­i­mous­ly rec­om­mend­ed the sep­a­ra­tion. San­doz gen­er­at­ed $9.1 bil­lion in 2022 net sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER